[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"steatotic-liver-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:steatotic-liver-disease":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100613763","screening-for-masld-related-advanced-fibrosis-in-type-2-diabetes-100613763",false,"NCT07270822","Screening for MASLD-related Advanced Fibrosis in Type 2 Diabetes","Implementation of a Systematic Screening for MASLD-related Advanced fibrosiS for Patients With Type 2 Diabetes folLoweD by DIABetologists","MASLD-DIAB","Inclusion Criteria:\n\n* Adult patient, male or female\n* Type 2 diabetic patient, followed by a diabetologist in private practice participating in the study\n* Patient affiliated to a French or European healthcare insurance\n* Patient who agrees to be included in the study and who signs the informed consent form\n\nExclusion Criteria:\n\n* Evidence of advanced fibrosis (F3 or F4 fibrosis based on the results from previous liver biopsy F3 ou F4 or evidence of cirrhosis).\n* Evidence of other causes of chronic liver disease\n* Patient who does not understand French\u002F is unable to give consent,\n* Patient already included in a trial who may interfere with the study\n* The subject is a pregnant or nursing female\n* Minor patient\n* Patient deprived of liberty,\n* Patient admitted to a health or social establishment for purposes other than research\n* Mentally unbalanced patients, under supervision or guardianship,\n* Patient undergoing psychiatric care\n* Patient not affiliated to a healthcare insurance plan\n* Patient already included in this screening program in the previous 12 months","ALL","18 Years",{"count":20,"type":21},1714,"ESTIMATED","INTERVENTIONAL",[24],"NA","Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 25% of the global adult population, 25-30% of whom suffer from metabolic dysfunction-associated steatohepatitis (MASH), increasing the risk of progression to advanced fibrosis (AF) (fibrosis stage F3 or cirrhosis F4). Screening for AF is justified because it is associated with an increased risk of overall, hepatic, and cardiovascular mortality and therefore constitutes a public health issue.\n\nPatients with type 2 diabetes (T2D) are identified as a priority target for screening because they are at high risk of AF related to MASLD. The recommendations of the French Association for the Study of the Liver 2020 (afef.asso.fr), the European Association for the Study of the Liver (2024), the American Association of Clinical Endocrinology (2022), and the American Association of Diabetes (2025) all recommend a two-step screening process involving the FIB-4 biological score, followed by transient elastography (TE) if the FIB-4 score is \\> or = 1.30. Finally, if the TE is ≥8 kPa, the patient is considered to be at intermediate\u002Fhigh risk of AF requiring specialized care to confirm the diagnosis and implement appropriate management, including semi-annual screening for hepatocellular carcinoma in cases of cirrhosis Despite these recommendations, their application in clinical practice remains difficult and requires multidisciplinary collaboration between diabetologists and hepatologists, and between community and hospital sectors, particularly to access TE measures.\n\nSince 2018, the Lyon Sud diabetes department (Hospices Civils de Lyon) has implemented an in-hospital AF screening program using TE for T2D patients. However, this screening by private diabetologists has not yet been implemented, mainly due to the lack of a standardized care pathway and difficulty in accessing TE measurements.\n\nHYPOTHESIS The implementation of systematic and standardized AF screening in private diabetes practices, in two stages and using ET in diabetes care in accordance with recommendations, would significantly increase the identification of patients with AF and thus improve their access to specialized services and appropriate care.",[27,28],"Steatotic Liver Disease","Fibrosis of Liver",[30,31,32,33,34,35],"Metabolic dysfunction-associated steatotic liver disease","hepatic transient elastography","hepatic fibrosis","type 2 diabetes mellitus","screening","non-invasive tests","NOT_YET_RECRUITING","2026-04-02",{"date":39,"type":40},"2026-04-03","ACTUAL",{"date":42,"type":21},"2026-05-01",{"date":44,"type":21},"2029-03-01",{"name":46,"class":47},"Hospices Civils de Lyon","OTHER",10,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":58,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":65,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":83},"100585837","long-term-follow-up-to-determine-outcome-in-liver-disease-love-study-100585837","NCT06907563","Long-term Follow-up to Determine Outcome in Liver Disease (LOVE Study)","LOVE","Inclusion Criteria:\n\n* Previous Informed consent for cohort studies\n* \\> 18 years of age\n* Diagnosis of SLD (MASLD, MetALD, ALD)\n\nExclusion Criteria:\n\n* No consent for previous cohort studies\n* \\\u003C 18 years of age\n* No Diagnosis of SLD (MASLD, MetALD, ALD)",{"count":57,"type":21},30000,"10 Years","OBSERVATIONAL","The rational to conduct the LOVE study builds on the lack of available data on outcomes in steatotic liver disease in well characterized patients over a time frame of several years. At current limited data on liver-specific and overall outcome in patients with MASLD, MetALD and ALD are available. Liver histology is the only accepted surrogate to reasonably likely predict outcomes in patients with non-cirrhotic liver disease and is currently used in regulatory trials. To overcome the limitations of liver biopsy and use validated non-invasive tests (NITs) to predict outcomes, the LOVE study will be conducted based on existing cohort studies in well pheno- and genotyped patients and will inform on the relevant outcomes based on baseline and ongoing biomarker assessment. The overarching goal is to qualify a NIT for patient identification and preventive measures in the regulatory context.",[27,62,63,64],"MASLD\u002FMASH (Metabolic Dysfunction-Associated Steatotic Liver Disease \u002F Metabolic Dysfunction-Associated Steatohepatitis)","Steatotic Liver Disease of Mixed Origin (MetALD)","ALD - Alcoholic Liver Disease",[66,67,68,69,70,71,72,73],"MASH","SLD","NITs","MASLD","ALD","MetALD","Metabolism","Liver","2025-03-26",{"date":76,"type":40},"2025-04-02",{"date":78,"type":21},"2025-04-15",{"date":80,"type":21},"2035-12-31",{"name":82,"class":47},"Universität des Saarlandes",4]